Background: Tumour necrosis factor α (TNFα) is a major therapeutic target in a range of chronic inflammatory disorders characterised by a Th1 type immune response in which TNFα is generated in excess.

INmune Bio's ATM offering raises $19M ahead of Phase II results, but disappointing data and dilution signal risks. Read here for more on INMB stock.